<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563939</url>
  </required_header>
  <id_info>
    <org_study_id>12-02</org_study_id>
    <nct_id>NCT01563939</nct_id>
  </id_info>
  <brief_title>Patient-controlled Intravenous Analgesia With Remifentanil Infusion for Labour</brief_title>
  <official_title>Patient-controlled Intravenous Analgesia With Remifentanil Infusion for Labour: is Demand Bolus Required for Optimal Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidural analgesia for pain relief in labor may not be suitable for all patients, and
      intravenous patient controlled analgesia (IV PCA) with opioids offers the best alternative.
      The purpose of this study is to assess the effectiveness of two methods remifentanil
      administration in the form of either an infusion or PCA demand bolus (intravenous injection
      of a single dose over a short period of time). Currently, our hospital gives remifentanil by
      demand bolus, however it may be equally effective, with less side effects, to give the drug
      as an infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted as a randomized trial with two arms: Group I- continuous infusion
      of remifentanil with stepwise increase in infusion rates and Group II- demand bolus only with
      stepwise increase in bolus dose, as per the patient's analgesic requirement. Visual analog
      scores will be the primary outcome. Maternal and fetal side effects will be recorded. The
      results of this study will determine the regimen that suits the patients needs for painless
      labor with high efficacy, less adverse effects and a higher patient satisfaction.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficult recruitment.
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>24 hours</time_frame>
    <description>Verbal Numeric Rating Scale (VNRS) from 0 to 10 (where 0 = no pain and 10 = worst pain felt), approximately every hour, throughout labour.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal satisfaction</measure>
    <time_frame>24 hours</time_frame>
    <description>Maternal satisfaction rated from 0-10, throughout labour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of remifentanil</measure>
    <time_frame>24 hours</time_frame>
    <description>remifentanil consumed in mg/hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crossover to epidural</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to crossover if the patient decides to have an epidural</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>24 hours</time_frame>
    <description>Sedation score, Heart Rate, Blood Pressure, Nausea, Vomiting, Pruritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal &amp; Neonatal outcomes</measure>
    <time_frame>48 hours</time_frame>
    <description>Non-reassuring fetal heart rate as determined by obstetrician, Neonatal weight, Apgar scores, naloxone administration, need for resuscitation, NICU admission.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Continuous infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanil administered by continuous IV infusion, with stepwise increase in infusion rates and placebo demand bolus of normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Demand Bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Demand bolus of remifentanil with stepwise increase in bolus dose and placebo continuous infusion of normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.
Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg.</description>
    <arm_group_label>Continuous infusion</arm_group_label>
    <arm_group_label>Demand Bolus</arm_group_label>
    <other_name>remifentanil hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Term pregnancy in labour with singleton fetus in cephalic presentation

          -  Patients requesting systemic analgesia

          -  Patients with contraindication for regional anesthesia without fetal compromise
             (coagulopathy, thrombocytopenia, refusal, etc.)

        Exclusion Criteria:

          -  Refusal to sign written informed consent

          -  Inability to communicate in English

          -  Opioid dependence or addiction

          -  Patients on Methadone

          -  Allergy or hypersensitivity to remifentanil

          -  Fetal heart rate abnormalities

          -  Fetal congenital anomalies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mrinalini Balki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>September 2, 2015</last_update_submitted>
  <last_update_submitted_qc>September 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Labour analgesia</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>IVPCA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

